Abstract
To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The Second ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on management of patients with nonsmall- cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, early stage disease, locally advanced disease and advanced (metastatic) disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on recommendations for pathology and molecular biomarkers in relation to the diagnosis of lung cancer, primarily non-small-cell carcinomas.
| Original language | English |
|---|---|
| Pages (from-to) | 1681-1690 |
| Number of pages | 10 |
| Journal | Annals of Oncology |
| Volume | 25 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 2014 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Consensus
- ESMO
- Molecular testing
- Non-small-cell lung cancer
- Pathology
- Recommendations
Fingerprint
Dive into the research topics of 'Second ESMO consensus conference on lung cancer: Pathology and molecular biomarkers for non-small-cell lung cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver